Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 55 44 15 73
Coronary Artery Stenosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4248
MeSH 44 D023921
NCIt 50 C80427
SNOMED-CT 68 233970002
UMLS 73 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to kawasaki disease and aortic aneurysm, familial abdominal, 1, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Lipoprotein metabolism and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Ticlopidine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and cardiovascular system

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 kawasaki disease 30.6 ALB CRP IL6
2 aortic aneurysm, familial abdominal, 1 30.2 APOE CRP IL6
3 angina pectoris 29.7 ACE CRP IL6 SERPINE1 VWF
4 myocarditis 29.5 ICAM1 IL6 TNNI3
5 chlamydia 29.3 CRP IL6 TLR4
6 aortic valve disease 2 29.2 ACE CRP TNNI3 VWF
7 acute myocardial infarction 29.0 ACE APOA1 CRP SERPINE1 TNNI3 VWF
8 pneumonia 29.0 CRP IL6 TLR4
9 crohn's disease 28.9 CRP IL6 TLR4
10 ischemic heart disease 28.6 ACE APOA1 APOB APOE CRP IL6
11 hypercholesterolemia, familial 27.4 APOA1 APOB APOE CETP CRP PCSK9
12 diabetes mellitus 27.0 ACE ALB APOA1 APOB CRP IL6
13 coronary heart disease 1 26.2 ACE APOA1 APOB APOE CETP CRP
14 heart disease 26.0 ACE ALB APOA1 APOB APOE CRP
15 diabetes mellitus, noninsulin-dependent 25.5 ACE ALB APOA1 APOB APOE CETP
16 coronary artery anomaly 25.4 ACE APOA1 APOB APOE CETP CRP
17 arteries, anomalies of 24.7 ACE ALB APOA1 APOB APOE CETP
18 myocardial infarction 23.3 ACE ALB APOA1 APOB APOE CETP
19 cold agglutinin disease 10.9 CRP IL6
20 moderate and severe traumatic brain injury 10.8 ACE APOE
21 diabetic foot ulcers 10.8 APOE IL6
22 cryopyrin-associated periodic syndrome 10.8 CRP IL6
23 cardiogenic shock 10.8 CRP IL6
24 acute cholangitis 10.7 CRP IL6
25 acute transverse myelitis 10.7 APOA1 IL6
26 neutrophilia, hereditary 10.7 CRP IL6
27 uremic pruritus 10.7 CRP IL6
28 hepatic lipase deficiency 10.6 APOA1 APOE
29 aortic disease 10.6 APOE CRP IL6
30 abdominal tuberculosis 10.6 ALB CRP
31 spinal disease 10.6 CRP IL6
32 generalized atherosclerosis 10.6 ACE APOE CRP
33 systolic heart failure 10.6 ACE CRP IL6
34 xanthoma disseminatum 10.6 APOB APOE
35 castleman disease 10.6 CRP IL6
36 blue toe syndrome 10.6 CRP SERPINE1
37 pyuria 10.5 ALB CRP
38 critical limb ischemia 10.5 IL6 VWF
39 cerebral atherosclerosis 10.5 ACE APOA1 APOE
40 hypercholesterolemia, autosomal dominant, type b 10.5 APOB APOE
41 defective apolipoprotein b-100 10.5 APOB APOE
42 acute cystitis 10.5 ALB CRP IL6
43 acute pyelonephritis 10.5 ALB CRP IL6
44 hemorrhagic fever with renal syndrome 10.5 ALB CRP IL6
45 chronic ulcer of skin 10.5 ALB CRP
46 appendicitis 10.4 ALB CRP IL6
47 dirofilariasis 10.4 CRP PON1 TNNI3
48 vascular dementia 10.4 ACE APOE PON1
49 familial lcat deficiency 10.4 ALB APOA1 APOE
50 bacterial meningitis 10.4 ALB CRP IL6

Graphical network of the top 20 diseases related to Coronary Stenosis:



Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:


angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.02 APOE CETP PCSK9 APOA1 APOB

MGI Mouse Phenotypes related to Coronary Stenosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 ICAM1 IL6 APOA1 APOB PON1 APOE
2 homeostasis/metabolism MP:0005376 10.18 ICAM1 ALB IL6 APOA1 APOB PCSK9
3 cellular MP:0005384 10.06 ICAM1 ALB APOA1 IL6 APOB PON1
4 immune system MP:0005387 9.97 ACE ICAM1 IL6 APOB APOE SERPINE1
5 liver/biliary system MP:0005370 9.91 ALB IL6 APOA1 APOB PCSK9 APOE
6 muscle MP:0005369 9.7 ICAM1 ALB IL6 APOB APOE TLR4
7 neoplasm MP:0002006 9.43 ICAM1 ALB IL6 SERPINE1 ACE TLR4
8 renal/urinary system MP:0005367 9.1 ACE ALB IL6 APOE SERPINE1 TLR4

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4,Phase 3,Not Applicable 55142-85-3 5472
2
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
3
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
4
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Regadenoson Approved, Investigational Phase 4,Phase 2,Not Applicable 313348-27-5 219024
9
Chromium Approved Phase 4,Phase 2,Phase 3,Not Applicable 7440-47-3 27668
10
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
11
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
12
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
13
Mycophenolic acid Approved Phase 4 24280-93-1 446541
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
16
Cilostazol Approved, Investigational Phase 4,Phase 3,Not Applicable 73963-72-1 2754
17
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
18
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
19
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
20
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
21
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
22
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 55-56-1 9552079 2713
25
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
26
Probucol Approved, Investigational Phase 4 23288-49-5 4912
27
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186
28
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
29
Ticagrelor Approved Phase 4 274693-27-5 9871419
30
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 1
31
Glucosamine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Not Applicable 3416-24-8 439213
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
33 Orange Approved, Nutraceutical Phase 4
34
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
35
Sarpogrelate Investigational Phase 4 125926-17-2 5160
36
Cobalt Phase 4,Phase 2,Phase 3,Not Applicable 7440-48-4 104729
37
Olmesartan medoxomil Phase 4 144689-63-4 130881
38 Analgesics Phase 4,Phase 3,Not Applicable
39 calcium channel blockers Phase 4,Not Applicable
40 diuretics Phase 4
41 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Respiratory System Agents Phase 4,Phase 3,Not Applicable
43 Adrenergic beta-Antagonists Phase 4
44 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
46 Glucuronyl glucosamine glycan sulfate Phase 4,Phase 2,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Cyclooxygenase 2 Inhibitors Phase 4
49 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 455)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Intravascular Ultrasound Unknown status NCT01133015 Phase 4
2 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
3 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
4 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
5 Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant Unknown status NCT00695344 Phase 4 everolimus;azathioprine or mycophenolate mofetil
6 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
7 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
8 ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial Unknown status NCT01121341 Phase 4
9 Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions Unknown status NCT01278186 Phase 4
10 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
11 SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents Unknown status NCT00714545 Phase 4
12 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
13 A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
14 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
15 Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis Completed NCT02602600 Phase 4 Liraglutide
16 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
17 Contrast Enhancement on Coronary Computed Tomographic Angiography Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
18 Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Completed NCT02120859 Phase 4
19 Kidney Damage in Patients With Normal eGFR Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
20 Kidney Damage in Patients With Moderate Fall in eGFR Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
21 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
22 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
23 Vision II: Evaluation of GALILEO Intravascular Radiotherapy System Completed NCT00180583 Phase 4
24 The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers Completed NCT00494559 Phase 4 Pioglitazone;Placebo
25 Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance Completed NCT01582165 Phase 4 Rosuvastatin;Placebo.
26 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
27 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth Completed NCT00349895 Phase 4
28 Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents Completed NCT00627900 Phase 4
29 Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel Completed NCT02140801 Phase 4 Ticagrelor;Clopidogrel
30 Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients Completed NCT01186107 Phase 4
31 Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
32 Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
33 Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study) Completed NCT00375063 Phase 4
34 EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT00531011 Phase 4
35 Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents Completed NCT01056744 Phase 4
36 Sirolimus-Eluting Stent Versus Standard Stent in Diabetic Completed NCT00755443 Phase 4
37 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
38 Effect of Ticagrelor on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
39 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Completed NCT01066650 Phase 4
40 Austrian Multivessel Taxus-Stent Registry Completed NCT00738686 Phase 4
41 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
42 QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia Completed NCT00150826 Phase 4 Quinapril;Placebo
43 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
44 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
45 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population Completed NCT01331707 Phase 4
46 Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
47 XIENCE V: SPIRIT WOMEN Sub-study Completed NCT01182428 Phase 4
48 XIENCE V: SPIRIT WOMEN Completed NCT00496938 Phase 4
49 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
50 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

41
Heart, Testes, Endothelial, Kidney, Liver, Monocytes, Brain

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 635)
# Title Authors Year
1
Cardiogoniometry Compared to Fractional Flow Reserve at Identifying Physiologically Significant Coronary Stenosis: The CARDIOFLOW Study. ( 29651685 )
2018
2
Quantitative baseline CT plaque characterization of unrevascularized non-culprit intermediate coronary stenosis predicts lesion volume progression and long-term prognosis: A serial CT follow-up study. ( 29548539 )
2018
3
Saline induced Pd/Pa ratio predicts functional significance of coronary stenosis assessed using fractional flow reserve. ( 29688181 )
2018
4
Delayed flow-mediated vasodilation and critical coronary stenosis. ( 29550752 )
2018
5
CT morphological index provides incremental value to machine learning based CT-FFR for predicting hemodynamically significant coronary stenosis. ( 29885695 )
2018
6
Deferred vs. performed revascularization for coronary stenosis with grey-zone fractional flow reserve values: data from the IRIS-FFR registry. ( 29529177 )
2018
7
The characteristics of coronary stenosis in 11,267 patients from Southwest China: a retrospective study. ( 29019045 )
2018
8
Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evaluated by fractional flow reserve. ( 29028737 )
2018
9
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. ( 29308090 )
2018
10
Evolving Routine Standards in InvasiveA Hemodynamic Assessment of Coronary Stenosis: TheA Nationwide Italian SICI-GISE Cross-Sectional ERIS Study. ( 29803695 )
2018
11
Diagnostic Concordance and Clinical Outcomes in Patients Undergoing Fractional Flow Reserve and Stress Echocardiography for the Assessment of Coronary Stenosis of Intermediate Severity. ( 29246509 )
2018
12
Fully quantitative pixel-wise analysis of cardiovascular magnetic resonance perfusion improves discrimination of dark rim artifact from perfusion defects associated with epicardial coronary stenosis. ( 29514708 )
2018
13
Combined Assessment of Stress Myocardial Perfusion Cardiovascular Magnetic Resonance and Flow Measurement in the Coronary Sinus Improves Prediction of Functionally Significant Coronary Stenosis Determined by Fractional Flow Reserve in Multivessel Disease. ( 29432130 )
2018
14
Computation of hemodynamics in eccentric coronary stenosis: A morphological parametric study. ( 29660973 )
2018
15
Invasive physiological indices to determine the functional significance of coronary stenosis. ( 29876502 )
2018
16
Fractional flow reserve-CT assessment of coronary stenosis. ( 29569282 )
2018
17
Calcification remodeling index assessed by cardiac CT predicts severe coronary stenosis in lesions with moderate to severe calcification. ( 28988831 )
2018
18
A new CFD based non-invasive method for functional diagnosis of coronary stenosis. ( 29566702 )
2018
19
Diagnostic accuracy of ASLA score (a novel CT angiographic index) and aggregate plaque volume in the assessment of functional significance of coronary stenosis. ( 29907444 )
2018
20
Fusion of Three-Dimensional Echocardiographic Regional Myocardial Strain with Cardiac Computed Tomography for Noninvasive Evaluation of the Hemodynamic Impact of Coronary Stenosis in Patients with Chest Pain. ( 29576220 )
2018
21
Beta 2-Microglobulin and the Severity of Coronary Stenosis in Patients With Acute Coronary Syndrome. ( 29573958 )
2018
22
Difference of coronary stenosis severity between systolic and diastolic phases in quantitative CT angiography. ( 28126251 )
2017
23
Sestrins increase in patients with coronary artery disease and associate with the severity of coronary stenosis. ( 28732653 )
2017
24
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). ( 28794001 )
2017
25
Bioresorbable Scaffolds for Coronary Stenosis: When and How Based Upon Current Studies. ( 28299676 )
2017
26
Efficacy of Optical Coherence Tomography-derived Morphometric Assessment in Predicting the Physiological Significance of Coronary Stenosis: Head-to-Head Comparison with Intravascular Ultrasound. ( 29155383 )
2017
27
Applicability of 3-Dimensional Quantitative Coronary Angiography-Derived Computed Fractional Flow Reserve for Intermediate Coronary Stenosis. ( 28331135 )
2017
28
Intravascular Images of Coronary Stenosis with Multiple Channels in a Patient with Antiphospholipid Syndrome: The Optical Coherence Tomography Findings. ( 28566597 )
2017
29
Clues to Discordance and Dissimilarity Between Coronary Stenosis and Lesion-Specific Ischemia. ( 28687541 )
2017
30
Outcomes of Coronary Artery Bypass and Stents for Unprotected Left Main Coronary Stenosis. ( 28223049 )
2017
31
Coronary Stenosis after Kawasaki Disease: Size Matters. ( 29248184 )
2017
32
An investigation of correlation between left coronary bifurcation angle and hemodynamic changes in coronary stenosis by coronary computed tomography angiography-derived computational fluid dynamics. ( 29184766 )
2017
33
Intermediate CD14(++)CD16(+) monocyte predicts severe coronary stenosis and extensive plaque involvement in asymptomatic individuals. ( 28239800 )
2017
34
Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. ( 29113395 )
2017
35
Effect modification of hypertension on the association of vitamin D deficiency with severity of coronary stenosis. ( 29254371 )
2017
36
Diagnostic Accuracy of Angiography-Based Quantitative FlowA Ratio Measurements for Online AssessmentA of Coronary Stenosis. ( 29101020 )
2017
37
Propensity-Score Matched Comparison of Midterm Angiographic Outcomes of Sirolimus- Versus Everolimus- and Biolimus-Eluting Stents for De Novo Coronary Stenosis. ( 28484124 )
2017
38
Stenotic flow reserve derived from quantitative coronary angiography has modest but incremental value in predicting functionally significant coronary stenosis as evaluated by fractional flow reserve. ( 28164013 )
2017
39
Electronic Stethoscope for Coronary Stenosis Detection. ( 28431676 )
2017
40
Extent of Coronary Stenosis and Anxiety Symptoms among Patients Undergoing Coronary Angiography. ( 29576782 )
2017
41
Noninvasive measurement of pressure gradient across a coronary stenosis using phase contrast (PC)-MRI: A feasibility study. ( 28019028 )
2017
42
Correction to: Assessing Computational Fractional Flow Reserve From Optical Coherence Tomography in Patients With Intermediate Coronary Stenosis in the Left Anterior Descending Artery. ( 28062519 )
2017
43
Three-year follow-up of patients with acetylcholine-induced coronary artery spasm combined with insignificant coronary stenosis. ( 28457560 )
2017
44
What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis? ( 28903135 )
2017
45
Left main coronary stenosis: surgery still reigns. ( 28797009 )
2017
46
Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischemic heart disease. ( 28485281 )
2017
47
Chronic Periaortitis of Ascending Aorta With Bilateral Ostial Coronary Stenosis in a Young Female. ( 28431717 )
2017
48
Quantification of left coronary bifurcation angles and plaques by coronary computed tomography angiography for prediction of significant coronary stenosis: A preliminary study with dual-source CT. ( 28346530 )
2017
49
Young Athlete With Complex Aneurysmal Coronary Stenosis. ( 29207369 )
2017
50
Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. ( 28905113 )
2017

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.17 ALB APOA1 APOB APOE CETP PCSK9
2 11.86 ALB IL6 TNNI3
3 11.79 ICAM1 IL6 TLR4
4 11.73 ALB APOA1 APOE TNNI3
5 11.7 IL6 SERPINE1 TLR4
6 11.68 ICAM1 IL6 SERPINE1
7
Show member pathways
11.64 ICAM1 IL6 TLR4
8 11.61 ICAM1 IL6 TLR4
9
Show member pathways
11.57 ALB APOA1 APOB APOE
10
Show member pathways
11.56 ALB APOA1 APOB APOE CRP ICAM1
11
Show member pathways
11.43 APOA1 APOB APOE CETP PCSK9
12 11.32 ICAM1 IL6 TLR4
13 11.29 APOB ICAM1 IL6
14 11.12 APOA1 ICAM1 IL6
15 11.05 ACE APOE TLR4
16 10.83 CRP IL6

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 9.91 APOA1 APOB APOE PCSK9 TLR4
2 extracellular matrix GO:0031012 9.89 APOA1 APOE ICAM1 SERPINE1 VWF
3 blood microparticle GO:0072562 9.84 ALB APOA1 APOE PON1
4 endoplasmic reticulum lumen GO:0005788 9.8 ALB APOA1 APOB APOE IL6 PCSK9
5 extracellular region GO:0005576 9.73 ACE ALB APOA1 APOB APOE CETP
6 platelet alpha granule lumen GO:0031093 9.72 ALB SERPINE1 VWF
7 very-low-density lipoprotein particle GO:0034361 9.65 APOA1 APOB APOE
8 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
9 low-density lipoprotein particle GO:0034362 9.61 APOA1 APOB APOE
10 chylomicron GO:0042627 9.58 APOA1 APOB APOE
11 spherical high-density lipoprotein particle GO:0034366 9.56 APOA1 PON1
12 discoidal high-density lipoprotein particle GO:0034365 9.52 APOA1 APOE
13 high-density lipoprotein particle GO:0034364 9.46 APOA1 APOE CETP PON1
14 intermediate-density lipoprotein particle GO:0034363 9.43 APOA1 APOB APOE
15 extracellular space GO:0005615 9.4 ACE ALB APOA1 APOB APOE CETP
16 extracellular exosome GO:0070062 10.11 ACE ALB APOA1 APOB APOE CETP

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.97 ALB APOA1 APOB APOE IL6 PCSK9
2 receptor-mediated endocytosis GO:0006898 9.93 ALB APOA1 APOB APOE
3 cellular response to lipopolysaccharide GO:0071222 9.91 ICAM1 IL6 SERPINE1 TLR4
4 lipid transport GO:0006869 9.91 APOA1 APOB APOE CETP
5 platelet degranulation GO:0002576 9.9 ALB APOA1 SERPINE1 VWF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 ICAM1 IL6 TLR4
7 defense response to Gram-negative bacterium GO:0050829 9.85 IL6 SERPINE1 TLR4
8 retinoid metabolic process GO:0001523 9.81 APOA1 APOB APOE
9 steroid metabolic process GO:0008202 9.8 APOA1 APOB APOE CETP PCSK9
10 cellular protein metabolic process GO:0044267 9.8 ALB APOA1 APOB APOE IL6 PCSK9
11 triglyceride metabolic process GO:0006641 9.79 APOE CETP PCSK9
12 cholesterol transport GO:0030301 9.76 APOA1 APOB CETP
13 triglyceride homeostasis GO:0070328 9.75 APOA1 APOE CETP
14 triglyceride catabolic process GO:0019433 9.74 APOA1 APOB APOE
15 cholesterol efflux GO:0033344 9.73 APOA1 APOB APOE
16 reverse cholesterol transport GO:0043691 9.71 APOA1 APOE CETP
17 positive regulation of chemokine production GO:0032722 9.7 IL6 TLR4
18 positive regulation of lipid biosynthetic process GO:0046889 9.7 APOA1 APOE
19 phosphatidylcholine metabolic process GO:0046470 9.7 APOA1 CETP PON1
20 positive regulation of cholesterol efflux GO:0010875 9.69 APOE PON1
21 negative regulation of blood coagulation GO:0030195 9.69 APOE SERPINE1
22 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.69 CETP CRP
23 low-density lipoprotein particle remodeling GO:0034374 9.69 APOB APOE CETP
24 high-density lipoprotein particle assembly GO:0034380 9.68 APOA1 APOE
25 heart contraction GO:0060047 9.68 ACE TNNI3
26 phospholipid efflux GO:0033700 9.68 APOA1 APOE
27 neutrophil mediated immunity GO:0002446 9.67 ACE IL6
28 negative regulation of lipid storage GO:0010888 9.67 CRP IL6
29 positive regulation of cholesterol esterification GO:0010873 9.67 APOA1 APOE
30 high-density lipoprotein particle clearance GO:0034384 9.66 APOA1 APOE
31 phospholipid homeostasis GO:0055091 9.66 APOA1 CETP
32 neuron projection regeneration GO:0031102 9.65 APOA1 APOE
33 chylomicron remnant clearance GO:0034382 9.65 APOB APOE
34 regulation of cholesterol transport GO:0032374 9.65 APOA1 APOE
35 chylomicron assembly GO:0034378 9.65 APOA1 APOB APOE
36 cholesterol homeostasis GO:0042632 9.65 APOA1 APOB APOE CETP PCSK9
37 regulation of Cdc42 protein signal transduction GO:0032489 9.64 APOA1 APOE
38 very-low-density lipoprotein particle clearance GO:0034447 9.63 APOB APOE
39 very-low-density lipoprotein particle remodeling GO:0034372 9.63 APOA1 APOE CETP
40 lipoprotein catabolic process GO:0042159 9.62 APOB APOE
41 chylomicron remodeling GO:0034371 9.61 APOA1 APOB APOE
42 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.59 APOE PCSK9
43 lipoprotein biosynthetic process GO:0042158 9.54 APOA1 APOB APOE
44 lipoprotein metabolic process GO:0042157 9.46 APOA1 APOB APOE PCSK9
45 high-density lipoprotein particle remodeling GO:0034375 9.26 ALB APOA1 APOE CETP
46 cholesterol metabolic process GO:0008203 9.1 APOA1 APOB APOE CETP PCSK9 PON1
47 lipid metabolic process GO:0006629 10.02 APOA1 APOB APOE CETP PCSK9 PON1
48 positive regulation of gene expression GO:0010628 10 APOB CRP IL6 TLR4

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.72 ALB APOA1 APOB APOE CETP
2 cholesterol binding GO:0015485 9.58 APOA1 APOE CETP
3 phospholipid binding GO:0005543 9.56 APOA1 APOB APOE PON1
4 phospholipid transporter activity GO:0005548 9.51 APOA1 CETP
5 low-density lipoprotein particle binding GO:0030169 9.49 CRP PCSK9
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.48 APOA1 APOE
7 lipoprotein particle binding GO:0071813 9.46 APOA1 APOE
8 lipid transporter activity GO:0005319 9.46 APOA1 APOB APOE CETP
9 very-low-density lipoprotein particle receptor binding GO:0070326 9.43 APOE PCSK9
10 apolipoprotein receptor binding GO:0034190 9.37 APOA1 PCSK9
11 low-density lipoprotein particle receptor binding GO:0050750 9.26 APOB APOE CRP PCSK9
12 cholesterol transporter activity GO:0017127 8.92 APOA1 APOB APOE CETP

Sources for Coronary Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....